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Stephanie A Christenson1,2*†, Corry-Anke Brandsma3,4†, Joshua D Campbell1,5, Darryl A Knight6,7,
Dmitri V Pechkovsky6,8, James C Hogg6, Wim Timens3,4, Dirkje S Postma4,9, Marc Lenburg1,5 and Avrum Spira1,5Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease characterized by varying
degrees of emphysematous lung destruction and small airway disease, each with distinct effects on clinical
outcomes. There is little known about how microRNAs contribute specifically to the emphysema phenotype. We
examined how genome-wide microRNA expression is altered with regional emphysema severity and how these
microRNAs regulate disease-associated gene expression networks.
Methods: We profiled microRNAs in different regions of the lung with varying degrees of emphysema from 6
smokers with COPD and 2 controls (8 regions × 8 lungs = 64 samples). Regional emphysema severity was quantified
by mean linear intercept. Whole genome microRNA and gene expression data were integrated in the same
samples to build co-expression networks. Candidate microRNAs were perturbed in human lung fibroblasts in order
to validate these networks.
Results: The expression levels of 63 microRNAs (P < 0.05) were altered with regional emphysema. A subset,
including miR-638, miR-30c, and miR-181d, had expression levels that were associated with those of their predicted
mRNA targets. Genes correlated with these microRNAs were enriched in pathways associated with emphysema
pathophysiology (for example, oxidative stress and accelerated aging). Inhibition of miR-638 expression in lung
fibroblasts led to modulation of these same emphysema-related pathways. Gene targets of miR-638 in these
pathways were amongst those negatively correlated with miR-638 expression in emphysema.
Conclusions: Our findings demonstrate that microRNAs are altered with regional emphysema severity and
modulate disease-associated gene expression networks. Furthermore, miR-638 may regulate gene expression
pathways related to the oxidative stress response and aging in emphysematous lung tissue and lung fibroblasts.Background
Chronic obstructive pulmonary disease (COPD) is a
growing epidemic and currently the third leading cause
of death in the US [1]. Mechanisms leading to the devel-
opment of COPD are poorly understood, and there are
currently no effective therapies that modify long-term
lung function decline in patients with the disease.
The heterogeneity of COPD (that is, patients affected
by varying degrees of emphysema and small airway* Correspondence: stephanie.christenson@ucsf.edu
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article, unless otherwise stated.disease) may account for some of the difficulty in identi-
fying effective therapies [2]. Although COPD is diag-
nosed as airflow obstruction that is not fully reversible,
measurements of airflow obstruction are weakly correlated
with emphysema severity and provide no information on
regional differences in emphysema within the lung [3,4].
Emphysema is independently associated with poor clinical
outcomes and there is evidence of an emphysema-
predominant COPD phenotype in which airflow limitation
is less important [5]. Understanding the molecular dysregu-
lation leading to emphysema may lead to a better under-
standing of this phenotype and more targeted therapeutics.
Prior studies of global gene and microRNA expression
in COPD were based on airflow limitation [6-13]. Thus,
they were unable to capture the effects of emphysema
independent of small airway disease. Furthermore, asntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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they were unable to account for differences in gene ex-
pression associated with varying disease severity within
an individual’s lung. We have developed an approach to
quantify emphysema severity within different regions of
the lung from patients with severe COPD, using micro-
computed tomography (micro-CT) data to evaluate
mean linear intercept (Lm), a measure of alveolar destruc-
tion [14]. Using these Lm measurements, we recently
identified a signature of gene expression associated with
increasing regional emphysema severity within individual
lungs [15]. We found that many of these genes are in-
volved in biological pathways such as inflammation, extra-
cellular matrix (ECM) remodeling, and tissue repair.
Furthermore, we were able to predict novel therapeutics
using our emphysema gene signature and the Connectivity
Map, showing that the compound tripeptide Gly-His-Lys
(GHK) reversed the emphysema-associated gene expres-
sion changes [16]. However, the molecular mechanisms
responsible for the disease-associated changes in gene ex-
pression within the lung are not well understood.
MicroRNAs are 19 to 25 nucleotide non-coding RNAs
that regulate gene expression through inhibition of mRNA
translation or induction of mRNA degradation [17]. It is
thought that they fine tune complex regulatory networks
by inhibiting multiple genes at once [18,19]. They have re-
peatedly been implicated in lung disease and are altered
with airflow obstruction; however, their role in emphysema
is unclear [12,13,20]. MicroRNAs are beginning to be stud-
ied in clinical trials as potential biomarkers and therapeu-
tics; thus, understanding how they contribute to disease
pathology could lead to significant clinical impact [21].
In this study, we assessed whether microRNA expression
changes as regional emphysema severity increases within
an individual’s lung and whether these microRNA changes
regulate gene expression alterations associated with disease.
We performed microRNA profiling in the same lung tissue
samples in which we analyzed mRNA expression and eval-
uated the relationship between microRNA and mRNA
expression changes and emphysema severity. A candidate
microRNA, miR-638, was further studied in human lung
fibroblasts derived from patients with severe COPD to bet-
ter understand its role in regulating gene expression pat-
terns associated with emphysema pathogenesis in vivo.
Methods
A schematic of the study design is shown in Additional
file 1: Figure S1.
Sample acquisition and preparation
A detailed description of sample preparation and acquisi-
tion has been described previously [14,22]. Briefly, lungs
were obtained from six subjects undergoing lung trans-
plantation for severe COPD and two donors withoutCOPD. Lungs were cut into 2 cm slices along the axial
plane and a cluster of 1 cm cores was taken from each
slice. One core from each slice was evaluated by micro-
CT while RNA and microRNA were extracted from an ad-
jacent core. Emphysema severity was calculated for each
cluster by mean linear intercept (Lm), an estimate of al-
veolar size, using the micro-CT images. Approximately
1,000 contiguous images were obtained from each
scanned core and Lm was measured at 20 regularly spaced
intervals in each scan. Lm was calculated by placing a grid
of parallel lines over each image and determining the sum
of the length of all grid lines divided by the number of in-
tercepts between the alveolar septae and grid lines. Thus,
a high Lm corresponds to more severe emphysema as
there will be fewer alveolar septae for the grid lines to
intercept, and thus a lower denominator.
This study was approved by the institutional review
boards at University of British Columbia, Boston Univer-
sity Medical Campus, University of Groningen (for fibro-
blast work), and University of Pennsylvania (where lungs
were procured). The study conforms to the Helsinki
Declaration. Written informed consent for use of these
specimens and the relevant clinical and radiological data
required for this research were obtained from each pa-
tient prior to surgery and from the next of kin of the
persons whose donated lung was released for research.
RNA isolation and microarray processing
RNA was extracted from tissue cores and fractionated
into high molecular weight (mRNA-containing) and low
molecular weight (LMW; microRNA-containing) por-
tions using the miRNeasy mini kit (QIAGEN, Valencia,
CA, USA). RNA fraction integrity was assessed using the
Agilent 2100 Bioanalyzer and purity was measured using
the NanoDrop spectrophotometer.
LMW RNA (<200 ng ng) was processed and hybrid-
ized onto NCode version 3 microRNA microarrays (Invi-
trogen, Carlsbad, CA, USA) as previously described [23].
These arrays contained probes for 1,053 microRNAs from
6 species, including 467 human microRNAs, printed in
triplicate. Raw data were extracted using GenePix Pro 4.0
(Axon/Molecular Devices, Sunnyvale, CA, USA).
The mRNA data were generated using Human Exon
1.0 ST microarrays as described in our previously pub-
lished gene-expression study [15].
Microarray normalization
Raw microRNA data underwent preprocessing and filter-
ing as previously described [23]. Briefly, the data were
quantile normalized, and log transformed (limma pack-
age, Bioconductor, R) [24,25]. A microRNA probe was
called 'present' if its signal intensity was two standard
deviations above the average of the background probes
in the sample. MicroRNA probes were filtered out if
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two or three replicate probes were called present, the
median of the present replicates was taken to obtain a
single expression value within each sample. If 0 or 1
probes were called present, the microRNA was filtered
out. Samples were then filtered based on two quality
metrics: (1) principal component analysis, whereby sam-
ples were excluded if they were significant outliers based
on the first two principle components; and (2) present/
absent filtering, whereby samples were excluded if less
than 50% of all human microRNA probesets were 'ab-
sent' in the sample. Three samples were excluded by at
least one of these two quality metrics.
Transcript-level gene expression values were generated
for our previously published gene expression paper via the
robust multichip average (RMA) algorithm (affy package,
Bioconductor, R) [15,26]. Gene symbols were retrieved
using the Entrez Gene Custom chip definition file [27].
Raw data for microRNA and gene expression are publicly
available at the Gene Expression Omnibus (GEO) under
the accessions GSE49881 and GSE27597, respectively.
Data analysis
MicroRNA (and gene) expression values were related to
emphysema severity using linear mixed-effects models
that controlled for differences between patients and pos-
ition in the lung from which the sample was taken (nlme
package, Bioconductor, R) [28]. Two linear mixed effects
models were used:
miRNAi ¼ β0 þ βSlice  Sliceþ βPatient  Patientþ ε ð1Þ
miRNAi ¼ β0 þ βSlice  Sliceþ βLm  Lm
þ βPatient  Patientþ εi ð2Þ
where miRNAi is the response variable representing the
log2 expression of microRNA i. βPatient*Patient repre-
sents the random effect of 'patient', which controls for
samples originating from the same lung. βSlice*Slice is a
fixed effect that controls for the region in the lung the
sample came from (slice number from apex to base).
β0 is the intercept and εi is the error for miRNAi. In
Equation 2 there is a second fixed effect, βLm*Lm, which
controls for emphysema severity as defined by the nat-
ural log of Lm. miRNAi was associated with emphysema
severity if the model in Equation 2 (with the emphysema
term) fit better than the model in Equation 1 using a
likelihood ratio test. Adjustment for multiple compari-
sons was done by applying the Benjamini-Hochberg false
discovery rate (FDR) [29].
The correlation analysis between microRNAs and
mRNAs was done using the same equations with genes
('Genei') substituted as the response variable for micro-
RNAs ('miRNAi') and 'βmiRNA*miRNA' substituted as the
fixed effect 'βLm*Lm' in Equation 2. Thus, this analysisevaluated the correlation between each gene and each
microRNA after correction for patient and region of
lung. Correlated microRNA-gene pairs (FDR <0.25) were
filtered to include only microRNA-predicted target
gene pairs as determined by at least one of five target
prediction algorithms (Targetscan, Pictar, Tarbase, miR-
Base, and microRNA.org) [30-34]. The lenient FDR cut-
off of 0.25 for significance of microRNA-target gene
pairs (corresponding to P = 0.002) was used given the
hypothesis-generating nature of this correlation analysis.
Furthermore, genes were then filtered to include only
predicted targets, and targets were validated through
in vitro experiments.
Real time PCR validation
Differential expression of eight microRNAs was evalu-
ated with quantitative RT-PCR (qRT-PCR). Three to
four samples from two of the eight patients were used to
evaluate each microRNA. qRT-PCR was performed
using the Taq-Man Small RNA Assay (Applied Biosys-
tems) with 10 ng LMW RNA per manufacturer’s proto-
col for miR-181d, miR-30c, miR-150, miR18a-3p, miR-
211, miR-296-5p, miR-483-3p and miR-638. PCR was
carried out using the StepOnePlus Real-Time PCR sys-
tem with 40 cycles of amplification and data acquisition.
Samples were run in triplicate and normalized to U6.
Analysis was done using the comparative CT method
and expression levels were compared to microarray by
correlation analysis.
Pathway analysis
Gene set enrichment analysis (GSEA) was used to deter-
mine whether pathways that may be biologically import-
ant in COPD were associated with microRNAs in our
data set [35]. Canonical pathway gene sets were obtained
from the Molecular Signature Database (MSigDB) [36].
For each differentially expressed microRNA, a ranked
gene list was generated using the t-statistics from the
linear mixed effect models that correlated mRNA and
microRNA expression.
Isolation, culture, and microRNA transfection in primary
lung fibroblasts
Primary lung fibroblasts were cultured from peripheral
lung tissue of a subject with stage IV COPD undergoing
lung transplant surgery. Cells were isolated and charac-
terized using our explant technique as described previ-
ously [37]. Fibroblasts were cultured in complete culture
medium (Ham’s F12, 10% fetal bovine serum, penicillin,
streptomycin and glutamin (all from Lonza, Verviers,
Belgium)) and used for experiments after five passages.
Transfection experiments (n = 3) with miR-638 inhibi-
tors and controls were performed using the HiPerFect
transfection reagent (QIAGEN). In short, 2.5 × 105
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MicroRNA inhibitors in a final concentration of 50 nM
(QIAGEN) for mir-638 were added dropwise to the cells.
The Inhibitor negative control from QIAGEN was used
as the negative control. The transfection reagent was re-
moved after 24 hours and cells were washed with Ham’s
culture medium without fetal bovine serum and har-
vested using trypsin and used for RNA isolation. RNA
was isolated using the miRNeasy kit.
RNA was hybridized to Affymetrix Human Gene 1.0
ST arrays. Differential expression between inhibitor and
control experiments was determined by empirical Bayes-
moderated t-tests. Differences in overall expression of
miR-638 predicted targets between inhibitor and control
experiments was determined by two-tailed Kolmogorov-
Smirnov testing (limma, R) [24].
Pathway analysis in fibroblasts and comparison of
fibroblast and emphysema datasets
GSEA analysis was done to determine biological pathways
enriched with miR-638 inhibition. Genes were ranked by
fold change difference between control and inhibitor and
canonical pathway gene sets were run against this ranked
list. Our fibroblast dataset was compared to our emphy-
sema dataset by using a gene set created from the 100
most upregulated miR-638 predicted targets (by fold
change) between miR-638 inhibitor experiments and con-
trol experiments. This gene set was run against a list of
genes ranked by their correlation with miR-638.
Results
Study population
Eight sample pairs from different lung slices were ob-
tained from six subjects requiring lung transplant for
COPD and two organ donors (64 samples total). De-
tailed characteristics of subjects and lung specimens
were described previously and are shown in Additional
file 2 [15]. Briefly, the six subjects with COPD had a
forced expiratory volume in 1 second (FEV1) <25% pre-
dicted (severe disease). Subjects with COPD had higher
and more variable mean linear intercept (Lm) values for
their tissue samples than donors except for one subject
who had small airways disease without emphysema. All
subjects were former smokers except one donor. Four
samples were excluded from further analysis: one as an
outlier by Lm, the others as outliers by microRNA
microarray quality metrics.
MicroRNA expression is altered with regional emphysema
severity
After microarray preprocessing, 397 of the initial 467
human microRNAs were detected above background
and used for further analysis. Sixty-three microRNAs
were correlated with Lm and thus with regionalemphysema severity (P-value < 0.05, 20 expected by
chance at this threshold; Figure 1; Additional file 3). In
contrast, only 18 microRNAs were correlated with pos-
ition in the lung the sample came from (for example, ap-
ical or basal, P < 0.05), and only three of these 18
microRNAs correlated with Lm (Additional file 4). The
microRNAs upregulated with increasing emphysema se-
verity included broadly conserved and poorly conserved
microRNAs, with the most upregulated including miR-
520e and miR-302d from the miR-93 family, miR-92a,
miR-638, miR-211, and miR-150. The downregulated
microRNAs included clusters from several broadly con-
served families. These include Let-7c, Let-7d, Let-7e,
and Let-7f from the Let-7/miR-98 family, miR-181c and
miR-181d from the miR-181/4262 family, and miR-30a-
3p, miR-30c, miR-30e-5p, and miR-30e-3p from the
miR-30/384-5p family. The association with regional
emphysema severity was validated using qRT-PCR. Ex-
pression values derived from microarray and RT-PCR
data were significantly correlated for four of the eight
miRNAs (Pearson; P ≤ 0.05; Additional file 1: Figure S2)
and just below statistical significance but trending in the
correct direction for a fifth microRNA, miR-181d (P =
0.06). The expression of these five microRNAs and two
of the other three all trended in the expected direction
(same as in the array data) with increasing Lm.
Gene expression is correlated with microRNA expression
in the emphysematous lung
To identify which microRNAs may regulate gene expres-
sion associated with emphysema pathogenesis, we gener-
ated a microRNA-mRNA correlation network by integrating
the microRNA expression data with global mRNA ex-
pression data generated from the same lung specimens.
We found that 1,079 microRNA-mRNA pairs were signifi-
cantly correlated (371 negative correlations, 708 positive
correlations) using linear mixed effect models (FDR <0.25)
and were predicted to interact by at least one of five
sequence-based target prediction algorithms.
Of the 63 differentially expressed microRNAs, 51 had
at least one positively or negatively correlated predicted
target at FDR <0.25 (Figure 2; Additional file 5). The
most highly connected microRNAs in the network in-
cluded miR-638, miR-18a-3p, miR-483-3p, miR-181d,
and miR-30c, which had greater than 50 positively or
negatively correlated predicted targets, suggesting that
these microRNAs may be important regulators of gene
expression associated with emphysema severity.
MicroRNAs regulate pathways involved in COPD
pathogenesis
To gain insight into functional significance of the
microRNA-mRNA interactions, we next used GSEA to
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Figure 1 MicroRNA expression associated with emphysema severity. (A) Supervised clustering of 63 microRNAs significantly correlated with
emphysema progression (P < 0.05). Samples are arranged in columns from low Lm (white) to high Lm (black). Red indicates high relative
expression, blue indicates low relative expression. (B) Scatter plots of expression values plotted against Lm for three microRNAs. Colors indicate
different subjects. As shown in this plot, each of the microRNAs is correlated with Lm across all subjects. However, importantly each microRNA is
correlated with Lm within patients as well.
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mRNA target analysis showing both positive and negative
correlations, the significantly enriched canonical pathways
were almost all inversely correlated with upregulated
microRNAs, suggesting an inhibitory role for microRNAs
with increasing disease severity. Unsupervised hierarchical
clustering of the pathways significantly enriched amongst
upregulated microRNAs identified several distinct clusters
of downregulated functional categories associated with ex-
pression of multiple upregulated microRNAs, including
miR-638 (Figure 3). Pathway gene sets most downregu-
lated in emphysema, including those involved in cell sur-
face signaling and ECM maintenance (for example,
transforming growth factor β, integrin, and wnt-signaling),
were inversely correlated with the expression of multiple
upregulated microRNAs. We also identified additional
pathways important to emphysema pathology that wereinversely correlated with upregulated microRNAs, includ-
ing pathways in tissue and cell repair (for example, DNA
repair and synthesis, cell cycle maintenance and traverse,
RNA processing, and proteasome maintenance/ubiquiti-
nation), and mitochondrial biogenesis (for example, oxida-
tive phosphorylation, electron transport chain).
Inhibition of miR-638 in lung fibroblasts leads to overex-
pression of its predicted targets
We next examined the specific effects of miR-638 on the
expression of its predicted targets in primary human
lung fibroblasts obtained from a subject with severe
COPD, as fibroblasts play a key role in the aberrant tis-
sue repair and ECM maintenance observed in emphy-
sema pathogenesis [37,38]. miR-638 was chosen as it
had many correlated targets, was anti-correlated with






Figure 2 MicroRNA-mRNA co-expression network for the differentially expressed microRNAs. Diamonds represent microRNAs and green
circles represent target genes. Lines identify significant correlations between microRNA and gene expression patterns (FDR <0.25) with the
microRNA predicted to target the gene by at least one of five sequence-based prediction algorithms. Red lines indicate positive correlations and
blue lines indicate negative correlations. Red nodes indicate upregulated microRNA expression with increased emphysema severity, blue indicates
downregulation. The thickness of the line correlates to the number of algorithms that predict the interaction.
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to be expressed in normal human lung fibroblasts [39].
We knocked down miR-638 in primary human lung fi-
broblasts and measured global gene expression using
Affymetrix Human Gene 1.0 ST arrays. We observed a sig-
nificant enrichment of miR-638 predicted targets amongst
upregulated genes in miR-638 knockdown experiments
compared to controls (P = 2.6 × 10-10, Kolmogorov-Smirnov
test; Figure 4A). miR-638 inhibition caused modest changes
in the expression of many target genes (1.15 to 1.4 fold
change for significant genes in our experiments), similar to
previously published studies on microRNA transfection
[40,41].
miR-638 targets are involved in oxidative stress-related
pathways and are anti-correlated with miR-638 expression
in emphysematous lung tissue
To evaluate the functional significance of miR-638 ex-
pression in emphysema, we identified the canonical
pathways affected by miR-638 knock-down in fibro-
blasts, and studied the overlap with genes and pathways
correlated with miR-638 in emphysematous lung tissue.
GSEA analysis revealed enrichment of many of the samebiological pathways among the genes increased in fibro-
blasts after miR-638 inhibition as those whose expression
was anti-correlated with miR-638 expression in emphy-
sema (FDR <0.25; Figure 4C; Additional file 6: Table S5).
miR-638 inhibition in fibroblasts led to upregulation of
pathway gene sets involved in DNA repair, cell-cycle
maintenance and traverse, RNA transcription, mito-
chondrial biogenesis, telomere maintenance, and pro-
cessing of damaged proteins. Sixty-nine (56%) of these
pathways were also anti-correlated with miR-638 ex-
pression in emphysematous lung tissue, and previously
implicated in oxidative stress and accelerated lung
aging responses.
The 100 most upregulated predicted targets by fold
change with miR-638 inhibition in fibroblasts were enriched
amongst predicted targets anti-correlated with miR-638 ex-
pression in emphysema (P < 0.001, Kolmogorov-Smirnov
test; Figure 4B). These predicted targets included genes
involved in cell proliferation (ADAM15, ARHGDIA,
COMMD1, DHCR7, HDAC5, MAD2L2, PFKL, YPEL3),
autophagy and protein degradation (ATG9A, GANAB),
mitochondrial functioning (DHCR7, ERAL1, SLC25A1,











Canonical Pathway Gene Sets
Figure 3 MicroRNAs are inversely correlated with biological pathways downregulated with increasing regional emphysema severity.
Expression-based association matrix of the 35 significantly upregulated microRNAs (rows) and those MSigDB canonical pathway gene sets
(columns) that are significantly enriched amongst genes correlated with the microRNA (FDR <0.25). Red indicates positive correlation, blue
indicates negative correlation, and white indicates no significant correlation. The color bar at the top of the heatmap indicates pathways also
correlated with emphysema (FDR <0.25) where red indicates positive correlation and grey negative correlation. The grey and white bar below the
heatmap highlights clusters of downregulated pathways. The group of pathways indicated by bar 1 includes those most downregulated with
emphysema (for example, those involved in ECM maintenance and cell signaling). The second bar highlights an additional cluster of pathways
most anti-correlated with upregulated microRNA expression; it includes mainly pathways involved in RNA transcription and processing, cell cycle
progression, mitochondrial functioning, DNA repair, and protein degradation.
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and ECM remodeling (LTBP4). These results demon-
strate that by modulating miR-638 in lung fibroblasts
obtained from a patient with COPD, we can reproduce
emphysema-related patterns of gene expression ob-
served in lung tissue and further suggest a role for
miR-638 in emphysema pathogenesis.Discussion
In this study, we have shown that regional emphysema
severity is associated with alterations in microRNA ex-
pression and that a subset of these microRNA changes
are correlated with changes in their predicted gene tar-
get expression. While 51 of the 63 altered microRNAs
correlated with at least one of their predicted targets, a
A.  COPD fibroblast transfection with miR-638 inhibitor 
Expression Fold Change (log 2)








































Figure 4 Changes in miR-638 predicted target gene expression with mir-638 knockdown. (A) ECDF, (empirical cumulative distribution
function) plot showing the t-statistics from empirical bayes-moderated t-tests for miR-638 predicted target genes (red) versus all genes (black).
The predicted targets are shifted right from control in the inhibitor transfected samples, indicating the expected upregulation of target gene
expression. Expression of the predicted targets are significantly different between controls and inhibitors by two-sided Kolmogorov-Smirnov tests
(P-value = 2.576e-10). (B) Density plots of the t-statistics from correlations between miR-638 expression and gene expression in emphysematous
lung tissue for: (1) all genes (black), (2) all miR-638 predicted targets (red), and (3) those miR-638 predicted targets over-expressed in fibroblasts
with miR-638 knock-down (blue). The majority of miR-638 correlations are in the positive direction, consistent with the red line shifted right, while
the targets over-expressed with miR-638 inhibition are mostly anti-correlated, consistent with the blue line shifted left. (C) A magnified view of
the miR-638 row extracted from the expression matrix in Figure 4 shows the pathways positively and negatively correlated with miR-638
expression (red and blue, respectively). Pathways upregulated with miR-638 knock-down in fibroblasts are shown above this in blue. This illustrates
that many of the pathways overlap, particularly in the sets of pathways associated with cell cycle progression, RNA transcription, and
mitochondrial biogenesis (bar 1), and DNA repair (bar 2).
Christenson et al. Genome Medicine 2013, 5:114 Page 8 of 13
http://genomemedicine.com/content/5/12/114much smaller subset had many correlated targets. Five
of these microRNAs (miR-638, miR-181d, miR-18a-3p,
miR-30c, and miR-483-3p) were correlated with ≥50 of
their predicted targets, suggesting that these microRNAs
may play a key role in gene regulation in emphysema.
Unique strengths of our study include our ability to
relate microRNA changes to the emphysematous com-
ponent of COPD, to account for regional differences in
emphysema within an individual patient’s lung, and
to relate microRNA changes to mRNA changes within
these same samples. Other studies of microRNA expres-
sion in COPD have used airflow obstruction alone as
the COPD phenotype to associate with molecular alter-
ations [12,13]. However, emphysema correlates poorly
with severity of airflow obstruction and contributes in-
dependently to outcomes in COPD [2,4,42]. In addition,emphysematous destruction and small airway disease
occur to different degrees throughout the lungs of pa-
tients with COPD, and airflow obstruction measure-
ments cannot capture these differences. We isolated
multiple samples from regions within an individual pa-
tient’s lung varying by degree of emphysema and by lo-
cation (for example, apical, basal), and used Lm to
quantify the degree of emphysema severity within each
sample. By using this study design, we were able to spe-
cifically identify those microRNAs whose expression is
related to emphysema severity/progression within the
lung, controlling both for microRNA expression differ-
ences between individuals and for differences in lung lo-
cation the sample came from (for example, apical, basal).
Furthermore, the unique study design allowed us to
identify microRNA-mRNA networks that underlie the
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individual’s lung.
An analysis of microRNA-target interactions revealed
numerous significant negative and positive interactions
suggesting that microRNAs are an important part of the
regulatory network in emphysema. Somewhat surpris-
ingly, 66% of significant correlations were in the positive
direction. Although this seems counterintuitive, given
that microRNAs inhibit gene expression, positive corre-
lations are noted throughout the literature, including in
a study of human airway microRNA and gene expression
[19,43-45]. Positive correlations are attributed to micro-
RNAs acting together in a network with other regulatory
processes to influence gene expression (Additional file 1:
Figure S3). Both microRNAs and the mRNAs they dir-
ectly inhibit may be under the control of common up-
stream regulators. This can lead to positive correlation
between the expression of the microRNA and mRNA
pairs even though the microRNAs are functioning
to decrease mRNA expression levels in this context
(a coexpressed or 'incoherent' circuit). Negative microRNA-
target gene correlations suggest upregulated microRNAs
act with other processes to lower target gene expression
(an expected or 'coherent' circuit).
Our pathway analysis suggests microRNA-gene inter-
actions may contribute to emphysema pathogenesis by
influencing pathways involved in ECM maintenance,
the oxidative stress response and lung aging. The path-
way gene sets most downregulated with increasing
emphysema severity, including those involved in ECM
maintenance, were anti-correlated with upregulated
microRNA expression. In addition, pathways involved
in tissue repair processes (for example, DNA repair,
cell cycle traverse, and lysosome maintenance) and mito-
chondrial functioning, which are dysregulated in accelerat-
ing lung aging processes and critical to emphysema
pathogenesis, were also significantly enriched amongst
genes anti-correlated with upregulated microRNAs. Mul-
tiple microRNAs have previously been found to regulate
tissue repair processes and to act cooperatively or redun-
dantly to control these functions [46]. Our findings sup-
port this and suggest that dysregulation of multiple
microRNAs may contribute to emphysema pathogenesis.
We studied the function of miR-638, a microRNA
whose expression increases with increasing emphysema
severity, in regulating gene expression in human lung fi-
broblasts. Peripheral lung fibroblasts were studied as
they have been implicated in COPD as key regulators of
accelerated lung aging and dysregulated ECM repair.
Our analysis suggests that the microRNAs changing
with emphysema severity may be regulators of these
processes. Fibroblasts are the main producers of the
ECM and have been shown by us and others to be defi-
cient in collagen contraction, a model property of therepair process, in patients with COPD [37,38]. Acceler-
ated aging processes (for example, cellular senescence)
are upregulated in fibroblasts in COPD and have been
implicated as mediators of fibroblast functional insuffi-
ciency, and thus their decreased contribution to ECM
repair, in COPD [47]. miR-638 was chosen as it has
many correlated targets and was previously found to be
associated with cellular senescence and DNA damage
[39,48], suggesting it contributes to accelerated lung
aging as well. It is expressed in human lung fibroblasts
and its expression increases as a function of cellular sen-
escence [39]. miR-638 overexpression in bronchial epi-
thelial cells also increases DNA damage and decreases
DNA repair, both of which contribute to cellular senes-
cence and tissue repair dysregulation, after exposure to
benzo(a)pyrene, a polycyclic aromatic hydrocarbon and
component of cigarette smoke [48].
We found that miR-638 knock-down in COPD
fibroblasts preferentially leads to over-expression of its
predicted targets and that overexpressed targets are
enriched amongst gene targets anti-correlated with miR-
638 expression in emphysematous lung tissue. Thus, al-
though miR-638 is positively correlated with two-thirds
of its predicted targets in emphysema, those targets that
are most affected with modulation of this microRNA in
COPD fibroblasts are anti-correlated with miR-638 ex-
pression in emphysema. While the positive correlations
imply that miR-638 is part of a regulatory network
in which upstream regulators lead to microRNA-mRNA
target coexpression (incoherent regulatory circuit), we
show evidence that miR-638 is an important regulator
in the network as well, as it is anti-correlated with
those targets it directly inhibits most in COPD fibro-
blasts. These findings clearly suggest that miR-638
contributes to the gene expression changes related to
emphysema severity.
miR-638 inhibition in fibroblasts led to upregulation of
pathways that were also dysregulated in emphysematous
lung tissue and involved in responses consistent with ac-
celerated lung aging and the oxidative stress response.
Furthermore, several miR-638 gene targets involved
in these processes were dysregulated in vitro with miR-
638 inhibition and anti-correlated with miR-638 expres-
sion in lung tissue with increasing emphysema severity.
Accelerated aging, which can occur independently of
and earlier than chronological aging, is a collection
of molecular and cellular alterations that has been
implicated in several diseases (for example, emphysema,
Parkinson’s disease, diabetes, coronary artery disease).
Some of these processes include: (1) cellular senescence,
telomere attrition, persistent DNA damage response,
and cell cycle arrest, leading to decreased cell prolifera-
tion and stimulation of T-helper type 1-associated in-
flammation; (2) mitochondrial dysfunction leading to
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stress; and (3) decreased removal of damaged proteins
leading to further cellular senescence and increased tis-
sue damage [49-52]. Chronic exposure to cigarette
smoke leads to chronic oxidative stress that has been
implicated in turning on these aging processes prema-
turely. This is hypothesized to lead to the tissue destruc-
tion and inability to replace cells that we observe in
emphysema. Given our pathway and microRNA-target
interaction analyses, we propose that miR-638 contrib-
utes to accelerated lung aging and oxidative stress re-
sponses in emphysema (Figure 5).
While most studies of microRNAs in the lung show
regulation of just one or a few genes, a strength of our
study is that we are able to show that microRNAs can
alter the expression of multiple genes leading to path-
ology. Amongst these genes is HDAC5, which encodes
histone deacetylase 5, and has been shown to decrease
with increasing COPD severity. Through epigenetic
modification, this decrease in HDAC5 has been hypoth-
esized to contribute to cell cycle arrest and increased
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genes to contribute to disease. Additional studies are
needed to investigate how the microRNAs specifically
contribute to the emphysema phenotype. In addition,
given the vast public health impact of COPD, the scarcity
of treatment options, and the recent advances in the de-
velopment of microRNA-directed therapeutics, future
work may focus on these microRNAs as potential treat-
ment targets in emphysema. We have shown that the
downstream inhibition of multiple genes by at least one of
these microRNAs, miR-638, likely functions to affect em-
physema pathogenesis. Thus, targeting microRNAs in em-
physema may have a significant impact by altering the
expression of many genes relevant to disease pathogenesis.
Conclusions
This study demonstrates that microRNA expression is al-
tered with regional emphysema severity and that these
microRNAs can regulate the gene expression changes as-
sociated with emphysema. Our study design allowed us to
examine emphysematous destruction independent of air-
flow limitation and to control for heterogeneity of emphy-
sema severity between and within patients, which limited
previous analyses of microRNA expression in COPD. We
identified several microRNAs that may be involved in em-
physema pathogenesis and appear to modulate disease-
specific gene expression networks. We demonstrated that
miR-638, which was upregulated in emphysema, likely
participates in COPD pathology by responding to oxida-
tive stress, contributing to an accelerated lung aging re-
sponse and leading to an impaired ability of the damaged
lung to replace the damaged ECM. MicroRNAs identified
as important to emphysema pathogenesis are intriguing
candidates for further study in biomarker and therapeutic
target development in emphysema.
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